AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Alkaline phosphatase, tissue-nonspecific isozyme

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P05186

UPID:

PPBT_HUMAN

Alternative names:

Alkaline phosphatase liver/bone/kidney isozyme; Phosphoamidase; Phosphocreatine phosphatase

Alternative UPACC:

P05186; A1A4E7; B2RMP8; B7Z387; B7Z4Y6; O75090; Q2TAI7; Q59EJ7; Q5BKZ5; Q5VTG5; Q6NZI8; Q8WU32; Q9UBK0

Background:

Alkaline phosphatase, tissue-nonspecific isozyme (ALPL), plays a pivotal role in skeletal mineralization and adaptive thermogenesis. It hydrolyzes phosphate compounds, aiding in hydroxyapatite crystal formation, essential for bone and dental health. ALPL's broad substrate specificity includes natural substrates like diphosphate and pyridoxal 5'-phosphate, crucial for vitamin B6 metabolism.

Therapeutic significance:

ALPL is linked to Hypophosphatasia, a metabolic bone disease with varying severity, from lethal perinatal forms to milder adult manifestations. Understanding ALPL's function and its genetic variants opens avenues for targeted therapies, potentially transforming treatment paradigms for affected individuals.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.